{"id":300585,"date":"2026-10-12T09:42:47","date_gmt":"2026-10-12T04:12:47","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=300585"},"modified":"2026-10-12T09:42:47","modified_gmt":"2026-10-12T04:12:47","slug":"fredun-pharmaceuticals-vs-dil-vs-themis-medicare","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/fredun-pharmaceuticals-vs-dil-vs-themis-medicare\/","title":{"rendered":"Fredun Pharmaceuticals vs DIL vs Themis Medicare: Which Stock Should You Track"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Fredun Pharmaceuticals PE 57.90, mkt cap Rs 2,537 crore. DIL PE 27.21, mkt cap Rs 1,583 crore. Themis Medicare PE 25.17, mkt cap Rs 1,006 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Fredun Pharmaceuticals vs DIL vs Themis Medicare is a side-by-side comparison of three companies from the pharma and healthcare space. On this comparison, Fredun Pharmaceuticals carries a market capitalisation of about Rs 2,537 crore, against Rs 1,583 crore for DIL and Rs 1,006 crore for Themis Medicare, with return on equity of 11.73%, 17.67% and 0.42% respectively. Each company&#8217;s numbers are presented here without a declared preference, since the right stock depends on an investor&#8217;s own criteria.<\/p>\n<\/div>\n<p>Fredun Pharmaceuticals vs DIL vs Themis Medicare starts with the core numbers most investors compare within the pharma and healthcare segment: market capitalisation, valuation multiples, profitability, dividend yield and the latest quarterly results. Figures below are sourced as of October 2026 and will shift with daily price moves.<\/p>\n<p>All three names sit in the pharma and healthcare bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses. The sections below cover the company profiles, a valuation table, the latest quarter and a five-quarter trend for revenue and net profit.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=fredun-pharmaceuticals-vs-dil-vs-themis-medicare\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/fredun-pharmaceuticals-vs-dil-vs-themis-medicare\/#Fredun_Pharmaceuticals_DIL_and_Themis_Medicare_Company_Overview\" title=\"Fredun Pharmaceuticals, DIL and Themis Medicare: Company Overview\">Fredun Pharmaceuticals, DIL and Themis Medicare: Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/fredun-pharmaceuticals-vs-dil-vs-themis-medicare\/#Fredun_Pharmaceuticals_vs_DIL_vs_Themis_Medicare_Valuation_and_Profitability_Snapshot\" title=\"Fredun Pharmaceuticals vs DIL vs Themis Medicare: Valuation and Profitability Snapshot\">Fredun Pharmaceuticals vs DIL vs Themis Medicare: Valuation and Profitability Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/fredun-pharmaceuticals-vs-dil-vs-themis-medicare\/#Fredun_Pharmaceuticals_vs_DIL_vs_Themis_Medicare_Latest_Quarterly_Results\" title=\"Fredun Pharmaceuticals vs DIL vs Themis Medicare: Latest Quarterly Results\">Fredun Pharmaceuticals vs DIL vs Themis Medicare: Latest Quarterly Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/fredun-pharmaceuticals-vs-dil-vs-themis-medicare\/#Fredun_Pharmaceuticals_vs_DIL_vs_Themis_Medicare_Five-Quarter_Revenue_and_Net_Profit_Trend\" title=\"Fredun Pharmaceuticals vs DIL vs Themis Medicare: Five-Quarter Revenue and Net Profit Trend\">Fredun Pharmaceuticals vs DIL vs Themis Medicare: Five-Quarter Revenue and Net Profit Trend<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/fredun-pharmaceuticals-vs-dil-vs-themis-medicare\/#What_Should_Investors_Look_at_Beyond_These_Numbers\" title=\"What Should Investors Look at Beyond These Numbers?\">What Should Investors Look at Beyond These Numbers?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/fredun-pharmaceuticals-vs-dil-vs-themis-medicare\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/fredun-pharmaceuticals-vs-dil-vs-themis-medicare\/#FAQs_on_Fredun_Pharmaceuticals_vs_DIL_vs_Themis_Medicare\" title=\"FAQs on Fredun Pharmaceuticals vs DIL vs Themis Medicare\">FAQs on Fredun Pharmaceuticals vs DIL vs Themis Medicare<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/fredun-pharmaceuticals-vs-dil-vs-themis-medicare\/#What_is_the_market_cap_difference_between_Fredun_Pharmaceuticals_DIL_and_Themis_Medicare\" title=\"What is the market cap difference between Fredun Pharmaceuticals, DIL and Themis Medicare?\">What is the market cap difference between Fredun Pharmaceuticals, DIL and Themis Medicare?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/fredun-pharmaceuticals-vs-dil-vs-themis-medicare\/#What_are_the_PE_and_PB_ratios_of_Fredun_Pharmaceuticals_DIL_and_Themis_Medicare\" title=\"What are the PE and PB ratios of Fredun Pharmaceuticals, DIL and Themis Medicare?\">What are the PE and PB ratios of Fredun Pharmaceuticals, DIL and Themis Medicare?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/fredun-pharmaceuticals-vs-dil-vs-themis-medicare\/#Which_of_the_three_has_the_highest_ROE\" title=\"Which of the three has the highest ROE?\">Which of the three has the highest ROE?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/fredun-pharmaceuticals-vs-dil-vs-themis-medicare\/#Which_of_these_three_stocks_pays_the_highest_dividend_yield\" title=\"Which of these three stocks pays the highest dividend yield?\">Which of these three stocks pays the highest dividend yield?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/fredun-pharmaceuticals-vs-dil-vs-themis-medicare\/#What_is_the_debt_to_equity_ratio_for_Fredun_Pharmaceuticals_DIL_and_Themis_Medicare\" title=\"What is the debt to equity ratio for Fredun Pharmaceuticals, DIL and Themis Medicare?\">What is the debt to equity ratio for Fredun Pharmaceuticals, DIL and Themis Medicare?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/fredun-pharmaceuticals-vs-dil-vs-themis-medicare\/#What_were_the_latest_quarterly_revenue_and_net_profit_of_Fredun_Pharmaceuticals_DIL_and_Themis_Medicare\" title=\"What were the latest quarterly revenue and net profit of Fredun Pharmaceuticals, DIL and Themis Medicare?\">What were the latest quarterly revenue and net profit of Fredun Pharmaceuticals, DIL and Themis Medicare?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/fredun-pharmaceuticals-vs-dil-vs-themis-medicare\/#Does_this_comparison_recommend_one_of_Fredun_Pharmaceuticals_DIL_and_Themis_Medicare\" title=\"Does this comparison recommend one of Fredun Pharmaceuticals, DIL and Themis Medicare?\">Does this comparison recommend one of Fredun Pharmaceuticals, DIL and Themis Medicare?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Fredun_Pharmaceuticals_DIL_and_Themis_Medicare_Company_Overview\"><\/span><strong>Fredun Pharmaceuticals, DIL and Themis Medicare: Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Fredun Pharmaceuticals<\/strong> is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 2,537 crore, a return on equity of 11.73% and a book value of Rs 162.78 per share. Its quarterly revenue moved from Rs 119.85 crore in June 2025 to Rs 228.25 crore in June 2026, a change of +90.4%.<\/p>\n<p><strong>DIL<\/strong> is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 1,583 crore, a return on equity of 17.67% and a book value of Rs 138.15 per share. Its quarterly revenue moved from Rs 145.03 crore in June 2025 to Rs 126.19 crore in June 2026, a change of -13.0%.<\/p>\n<p><strong>Themis Medicare<\/strong> is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 1,006 crore, a return on equity of 0.42% and a book value of Rs 39.74 per share. Its quarterly revenue moved from Rs 98.76 crore in June 2025 to Rs 87.95 crore in June 2026, a change of -10.9%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Fredun_Pharmaceuticals_vs_DIL_vs_Themis_Medicare_Valuation_and_Profitability_Snapshot\"><\/span><strong>Fredun Pharmaceuticals vs DIL vs Themis Medicare: Valuation and Profitability Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/fredun\/fredun-pharmaceuticals-ltd-share-price-today\">Fredun Pharmaceuticals<\/a><\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/fermenta\/fermenta-biotech-ltd-share-price-today\">DIL<\/a><\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/themismed\/themis-medicare-ltd-share-price-today\">Themis Medicare<\/a><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Market Cap (approx.)<\/td>\n<td>Rs 2,537 crore<\/td>\n<td>Rs 1,583 crore<\/td>\n<td>Rs 1,006 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio (TTM)<\/td>\n<td>57.90<\/td>\n<td>27.21<\/td>\n<td>25.17<\/td>\n<\/tr>\n<tr>\n<td>PB Ratio<\/td>\n<td>9.43<\/td>\n<td>3.89<\/td>\n<td>2.75<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity (ROE)<\/td>\n<td>11.73%<\/td>\n<td>17.67%<\/td>\n<td>0.42%<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM, Rs)<\/td>\n<td>26.50<\/td>\n<td>19.77<\/td>\n<td>4.34<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>0.02%<\/td>\n<td>0.68%<\/td>\n<td>0.46%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.80<\/td>\n<td>0.28<\/td>\n<td>0.25<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share (Rs)<\/td>\n<td>162.78<\/td>\n<td>138.15<\/td>\n<td>39.74<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Data<\/strong><\/a><\/p>\n<p>On valuation, Fredun Pharmaceuticals trades at a PE of 57.90 and a PB of 9.43, DIL at a PE of 27.21 and a PB of 3.89, while Themis Medicare trades at a PE of 25.17 and a PB of 2.75. On return on equity, the three post 11.73%, 17.67% and 0.42% respectively, and on dividend yield they stand at 0.02%, 0.68% and 0.46%. Fredun Pharmaceuticals has the highest market capitalisation of the three at Rs 2,537 crore, while Themis Medicare has the lowest at Rs 1,006 crore. Fredun Pharmaceuticals has the highest PE ratio of the three at 57.90, while Themis Medicare has the lowest at 25.17. DIL has the highest return on equity of the three at 17.67%, while Themis Medicare has the lowest at 0.42%. Fredun Pharmaceuticals has the highest debt to equity ratio of the three at 0.80, while Themis Medicare has the lowest at 0.25. Debt to equity is 0.80, 0.28 and 0.25 for the three respectively.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Fredun_Pharmaceuticals_vs_DIL_vs_Themis_Medicare_Latest_Quarterly_Results\"><\/span><strong>Fredun Pharmaceuticals vs DIL vs Themis Medicare: Latest Quarterly Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Company<\/th>\n<th>Latest Quarter Revenue<\/th>\n<th>Latest Quarter Net Profit<\/th>\n<th>YoY Change (Revenue)<\/th>\n<th>QoQ Change (Revenue)<\/th>\n<th>YoY Change (Net Profit)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Fredun Pharmaceuticals<\/td>\n<td>Rs 228.25 crore<\/td>\n<td>Rs 13.13 crore<\/td>\n<td>+90.4%<\/td>\n<td>+7.1%<\/td>\n<td>+93.9%<\/td>\n<\/tr>\n<tr>\n<td>DIL<\/td>\n<td>Rs 126.19 crore<\/td>\n<td>Rs 9.53 crore<\/td>\n<td>-13.0%<\/td>\n<td>-0.4%<\/td>\n<td>-55.9%<\/td>\n<\/tr>\n<tr>\n<td>Themis Medicare<\/td>\n<td>Rs 87.95 crore<\/td>\n<td>Rs 24.61 crore<\/td>\n<td>-10.9%<\/td>\n<td>+9.7%<\/td>\n<td>NA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter. A percentage change in net profit is shown as NA where the comparison quarter was a loss or the latest quarter is a loss, since the percentage is not meaningful in that case.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Fredun_Pharmaceuticals_vs_DIL_vs_Themis_Medicare_Five-Quarter_Revenue_and_Net_Profit_Trend\"><\/span><strong>Fredun Pharmaceuticals vs DIL vs Themis Medicare: Five-Quarter Revenue and Net Profit Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The five-quarter view below shows how revenue and net profit moved from June 2025 to June 2026 for each company in Fredun Pharmaceuticals vs DIL vs Themis Medicare, which helps separate a one-quarter move from a steadier pattern.<\/p>\n<p><strong>Quarterly revenue (Rs crore)<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Fredun Pharmaceuticals<\/th>\n<th>DIL<\/th>\n<th>Themis Medicare<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>June 2025<\/td>\n<td>Rs 119.85 crore<\/td>\n<td>Rs 145.03 crore<\/td>\n<td>Rs 98.76 crore<\/td>\n<\/tr>\n<tr>\n<td>September 2025<\/td>\n<td>Rs 145.30 crore<\/td>\n<td>Rs 135.65 crore<\/td>\n<td>Rs 81.23 crore<\/td>\n<\/tr>\n<tr>\n<td>December 2025<\/td>\n<td>Rs 160.93 crore<\/td>\n<td>Rs 140.48 crore<\/td>\n<td>Rs 91.41 crore<\/td>\n<\/tr>\n<tr>\n<td>March 2026<\/td>\n<td>Rs 213.05 crore<\/td>\n<td>Rs 126.64 crore<\/td>\n<td>Rs 80.20 crore<\/td>\n<\/tr>\n<tr>\n<td>June 2026<\/td>\n<td>Rs 228.25 crore<\/td>\n<td>Rs 126.19 crore<\/td>\n<td>Rs 87.95 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Quarterly net profit (Rs crore)<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Fredun Pharmaceuticals<\/th>\n<th>DIL<\/th>\n<th>Themis Medicare<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>June 2025<\/td>\n<td>Rs 6.77 crore<\/td>\n<td>Rs 21.60 crore<\/td>\n<td>-Rs 14.22 crore<\/td>\n<\/tr>\n<tr>\n<td>September 2025<\/td>\n<td>Rs 9.43 crore<\/td>\n<td>Rs 18.03 crore<\/td>\n<td>-Rs 3.62 crore<\/td>\n<\/tr>\n<tr>\n<td>December 2025<\/td>\n<td>Rs 10.48 crore<\/td>\n<td>Rs 12.02 crore<\/td>\n<td>Rs 10.09 crore<\/td>\n<\/tr>\n<tr>\n<td>March 2026<\/td>\n<td>Rs 10.78 crore<\/td>\n<td>Rs 18.60 crore<\/td>\n<td>Rs 8.89 crore<\/td>\n<\/tr>\n<tr>\n<td>June 2026<\/td>\n<td>Rs 13.13 crore<\/td>\n<td>Rs 9.53 crore<\/td>\n<td>Rs 24.61 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Fredun Pharmaceuticals reported revenue of Rs 119.85 crore in June 2025 and Rs 228.25 crore in June 2026, a change of +90.4% across the period. Its highest quarterly revenue in this window was Rs 228.25 crore in June 2026. Net profit stood at Rs 13.13 crore in June 2026, which is a net profit margin of 5.75%.<\/p>\n<p>DIL reported revenue of Rs 145.03 crore in June 2025 and Rs 126.19 crore in June 2026, a change of -13.0% across the period. Its highest quarterly revenue in this window was Rs 145.03 crore in June 2025. Net profit stood at Rs 9.53 crore in June 2026, which is a net profit margin of 7.55%.<\/p>\n<p>Themis Medicare reported revenue of Rs 98.76 crore in June 2025 and Rs 87.95 crore in June 2026, a change of -10.9% across the period. Its highest quarterly revenue in this window was Rs 98.76 crore in June 2025. Net profit stood at Rs 24.61 crore in June 2026, which is a net profit margin of 27.98%. Themis Medicare reported a net loss in June 2025 and September 2025.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Fredun Pharmaceuticals, DIL and Themis Medicare live prices.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Should_Investors_Look_at_Beyond_These_Numbers\"><\/span><strong>What Should Investors Look at Beyond These Numbers?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Beyond the metrics above, investors comparing these three pharma and healthcare names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and factors specific to the segment such as regulatory approvals, export orders, raw material costs and the gap between reported profit and cash generation. A single-quarter snapshot can shift quickly, and smaller companies in particular can show wide swings from one quarter to the next.<\/p>\n<p>It also helps to read the latest quarterly filings and investor presentations of Fredun Pharmaceuticals, DIL and Themis Medicare directly, since the figures here come from standardised data and do not capture company-specific context such as one-time items, order timing or promoter actions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Fredun Pharmaceuticals vs DIL vs Themis Medicare highlights how differently three companies in the same pharma and healthcare segment can look across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information as of October 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Fredun_Pharmaceuticals_vs_DIL_vs_Themis_Medicare\"><\/span><strong>FAQs on Fredun Pharmaceuticals vs DIL vs Themis Medicare<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_market_cap_difference_between_Fredun_Pharmaceuticals_DIL_and_Themis_Medicare\"><\/span><strong>What is the market cap difference between Fredun Pharmaceuticals, DIL and Themis Medicare?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of October 2026, Fredun Pharmaceuticals has a market cap of approximately Rs 2,537 crore, DIL is at approximately Rs 1,583 crore, and Themis Medicare is at approximately Rs 1,006 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_PE_and_PB_ratios_of_Fredun_Pharmaceuticals_DIL_and_Themis_Medicare\"><\/span><strong>What are the PE and PB ratios of Fredun Pharmaceuticals, DIL and Themis Medicare?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of October 2026, the PE ratios stand at 57.90, 27.21 and 25.17 respectively, and the price to book ratios stand at 9.43, 3.89 and 2.75 respectively.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_the_three_has_the_highest_ROE\"><\/span><strong>Which of the three has the highest ROE?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Fredun Pharmaceuticals, DIL and Themis Medicare post ROE of 11.73%, 17.67% and 0.42% respectively as of October 2026. DIL has the highest return on equity of the three at 17.67%, while Themis Medicare has the lowest at 0.42%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_these_three_stocks_pays_the_highest_dividend_yield\"><\/span><strong>Which of these three stocks pays the highest dividend yield?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Fredun Pharmaceuticals, DIL and Themis Medicare carry dividend yields of 0.02%, 0.68% and 0.46% respectively.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_debt_to_equity_ratio_for_Fredun_Pharmaceuticals_DIL_and_Themis_Medicare\"><\/span><strong>What is the debt to equity ratio for Fredun Pharmaceuticals, DIL and Themis Medicare?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Fredun Pharmaceuticals carries a debt to equity of 0.80, DIL of 0.28, and Themis Medicare of 0.25.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_the_latest_quarterly_revenue_and_net_profit_of_Fredun_Pharmaceuticals_DIL_and_Themis_Medicare\"><\/span><strong>What were the latest quarterly revenue and net profit of Fredun Pharmaceuticals, DIL and Themis Medicare?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> For Q1 FY27 (quarter ended June 2026), Fredun Pharmaceuticals reported revenue of Rs 228.25 crore and net profit of Rs 13.13 crore, DIL reported revenue of Rs 126.19 crore and net profit of Rs 9.53 crore, and Themis Medicare reported revenue of Rs 87.95 crore and net profit of Rs 24.61 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Does_this_comparison_recommend_one_of_Fredun_Pharmaceuticals_DIL_and_Themis_Medicare\"><\/span><strong>Does this comparison recommend one of Fredun Pharmaceuticals, DIL and Themis Medicare?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor&#8217;s own criteria and research.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the market cap difference between Fredun Pharmaceuticals, DIL and Themis Medicare?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of October 2026, Fredun Pharmaceuticals has a market cap of approximately Rs 2,537 crore, DIL is at approximately Rs 1,583 crore, and Themis Medicare is at approximately Rs 1,006 crore.\"}},{\"@type\":\"Question\",\"name\":\"What are the PE and PB ratios of Fredun Pharmaceuticals, DIL and Themis Medicare?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of October 2026, the PE ratios stand at 57.90, 27.21 and 25.17 respectively, and the price to book ratios stand at 9.43, 3.89 and 2.75 respectively.\"}},{\"@type\":\"Question\",\"name\":\"Which of the three has the highest ROE?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Fredun Pharmaceuticals, DIL and Themis Medicare post ROE of 11.73%, 17.67% and 0.42% respectively as of October 2026. DIL has the highest return on equity of the three at 17.67%, while Themis Medicare has the lowest at 0.42%.\"}},{\"@type\":\"Question\",\"name\":\"Which of these three stocks pays the highest dividend yield?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Fredun Pharmaceuticals, DIL and Themis Medicare carry dividend yields of 0.02%, 0.68% and 0.46% respectively.\"}},{\"@type\":\"Question\",\"name\":\"What is the debt to equity ratio for Fredun Pharmaceuticals, DIL and Themis Medicare?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Fredun Pharmaceuticals carries a debt to equity of 0.80, DIL of 0.28, and Themis Medicare of 0.25.\"}},{\"@type\":\"Question\",\"name\":\"What were the latest quarterly revenue and net profit of Fredun Pharmaceuticals, DIL and Themis Medicare?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"For Q1 FY27 (quarter ended June 2026), Fredun Pharmaceuticals reported revenue of Rs 228.25 crore and net profit of Rs 13.13 crore, DIL reported revenue of Rs 126.19 crore and net profit of Rs 9.53 crore, and Themis Medicare reported revenue of Rs 87.95 crore and net profit of Rs 24.61 crore.\"}},{\"@type\":\"Question\",\"name\":\"Does this comparison recommend one of Fredun Pharmaceuticals, DIL and Themis Medicare?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Fredun Pharmaceuticals vs DIL vs Themis Medicare compared on market cap, PE, PB, ROE, dividend yield and debt to equity, as of October 2026.<\/p>\n","protected":false},"author":34,"featured_media":300583,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[11016,1019],"class_list":["post-300585","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-pharma-and-healthcare","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["300583"],"rank_math_title":["Fredun Pharmaceuticals vs DIL vs Themis Medicare"],"rank_math_description":["Fredun Pharmaceuticals vs DIL vs Themis Medicare compared on market cap, PE, PB, ROE, dividend yield and debt to equity, as of October 2026."],"rank_math_focus_keyword":["Fredun Pharmaceuticals vs DIL vs Themis Medicare"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/fredun-pharmaceuticals-vs-dil-vs-themis-medicare-which-stock-should-you-track.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/300585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=300585"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/300585\/revisions"}],"predecessor-version":[{"id":300586,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/300585\/revisions\/300586"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/300583"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=300585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=300585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=300585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}